ABSTRACT: A compound, triptophenolide, derived from Tripterygium wilfordii was identified as an antiandrogen. Triptophenolide inhibits the activity of both wild-type and F876L mutant ARs. Triptophenolide exhibits its anti-androgenic activity through competitive binding with androgen in the hormone-binding pocket, decreasing the expression of androgen receptor, and reducing the nuclear translocation of androgen receptor.
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Identification of triptophenolide from Tripterygium wilfordii as a pan-antagonist of androgen receptor
ABSTRACT: A compound, triptophenolide, derived from Tripterygium wilfordii was identified as an antiandrogen. Triptophenolide inhibits the activity of both wild-type and F876L mutant ARs. Triptophenolide exhibits its anti-androgenic activity through competitive binding with androgen in the hormone-binding pocket, decreasing the expression of androgen receptor, and reducing the nuclear translocation of androgen receptor.
Prostate cancer (PCa) is one of the most common cancers and the second leading cause of cancer death in men of the western countries 1 . Androgen receptor (AR) plays a critical role in the development and progression of PCa 2 . Antiandrogen has become a main therapeutic agent for advanced PCa. Up to now, current clinically used antiandrogens such as flutamide (FLU), bicalutamide (BIC), and newly approved enzalutamide (ENZ) mainly target the hormone-binding pocket (HBP) of the AR ligand binding domain (LBD). These approved antiandrogens have greatly improved the survival and life quality of the PCa patients. However, after the initial effective response, most tumors develop resistance to the antiandrogen used for therapy due to the AR overexpression 3 , the AR mutants [4] [5] [6] [7] , or the bypassing pathway activation 8, 9 , etc. Therefore, it is increasingly urgent to seek for the new strategy to obtain novel antiandrogens in order to circumvent the developed resistance of PCa for the current clinically used antiandrogens. On the other hand, traditional Chinese medicine (TCM) has a very long history in cancer therapy. To date, TCM is widely used as a complementary therapy for cancer and is found improving symptoms and the quality of life and even extend lifespan of cancer patients 10, 11 , thus providing a potential resource for therapeutic agents of prostate cancer. Importantly, one herb, Tripterygium wilfordii, apart from its application in the treatment of rheumatoid arthritis and other immune-mediated inflammatory diseases for the antiinflamatory and immunomodulatory activity 12, 13 , is also very frequently used in therapy of cancer in Chinese hospitals. Some natural products derived from the herb, such as celastrol 14, 15 and triptolide 16, 17 , were reported as potent anti-PCa agents. What is more, through a genomics-based phenotypic screening approach, triptophenolide was found as an effective inhibitor of AR 18 , however, the detailed anti-androgen mechanism remains unknown 18 . Herein, starting from the detection of the anti-androgen activity of ethanol extract of Tripterygium wilfordii root, we finally identified triptophenolide as a panantagonist for wild-type and mutant ARs, which inhibiting androgenic activity through competitive binding with androgen in the HBP of AR, decreasing the expression of androgen receptor, and reducing the nuclear translocation of AR. The strategy was shown in Scheme1. We tried to screen the antiandrogen from Tripterygium wilfordii through combining MTT assay and dual-luciferase assay. As a start, we inspected the antiandrogenic potency of Tripterygium wilfordii root ethanol extract through MTT and dual-luciferase assay. In MTT assay, both LNCaP (AR positive) and PC-3 (AR negative) cell lines were used to evaluate the anti-prostate cancer activity of the herb. As a result, Tripterygium wilfordii root extract inhibited the growth of the LNCaP cells rather than the PC-3 cells in a significant dose-dependent manner at the concentration range of 1.0-7. To inspect which components in Tripterygium wilfordii root should be responsible for the antiandrogen activity, we tested six main components from Tripterygium wilfordii, and the results were shown in FigS2. The luciferase assay of the AR activity in LNCaP cells revealed that all six components could significantly reduce the endogenous AR transcription activity (FigS2 A) at the concentration of 5 µM, and triptophenolide, triptolide, and triptonide displays significant anti-AR activity 2 potency at the concentration of 500 nM. As AR mutant F876L will cause the drug resistance of the clinical used antiandrogen ENZ 19 , we further investigated the antiandrogenic activities of all these six components against the F876L mutant AR. ARdependent reporter assays were performed in PC-3 cells using ARE (androgen receptor element) driven PSA-luc reporter and AR-expressing plasmids. Antiandrogen ENZ was included as the control. As a result, in the absence of dihydrotestosterone (DHT), the F876L mutated AR was activated by ENZ (FigS2 B), which was consistent to previous reports 20 . Only triptophenolide demonstrates the significant antiandrogenic activity in suppressing DHT-induced transcription of the endogenous F876L mutated AR at the concentration of 500 nM (FigS2 B). Thus we selected triptophenolide as a potential antiandrogen for further mechanism studies.
To further evaluate the antiandrogenic potency of triptophenolide, we investigated antiandrogenic activity of triptophenolide against wild-type (WT) and T877A (FLU resistance mutant), F876L, and W741C + T877A (FLU and BIC resistance mutant) mutated ARs in absence or presence of DHT at 50 nM, 500 nM, and 5 µM. As results, triptophenolide did not show any agonistic activity to both the wild type and mutated ARs in absence of DHT (Fig1 A-D, white bars). In presence of DHT, triptophenolide demonstrates effective antiandrogenic activity in suppressing DHT-induced transcriptions of the WT, the F876L, T877A, and W741C+ T877A AR mutants in a dose-dependent manner (Fig1 A-D, black bars), which indicates triptophenolide is a pan-antagonist against WT and mutated ARs (The results of the luciferase assay of the ARs activity for triptophenolide within the 0.1-25 µM concentration range were listed in Figure S3 ). We also evaluated the IC 50 value of triptophenolide against AR transcription activity. The result showed that triptophenolide has the IC 50 values of 260 nM for AR-WT, 480 nM for AR-F876L, 388 nM for AR-T877A, and 437 nM for W741C+T877A ( Figure S4 ), respectively. Next, the regulation of PSA at RNA level by triptophenolide was detected using RT-PCR in LNCaP cells. The results showed that triptophenolide significantly downregulated PSA mRNA level at 500 nM and 5 µM (Fig1E, the measured value of RT-PCR assay were listed in Table S3 ). It means that the inhibition of the PSA expression by triptophenolide is modulated at mRNA level. Next, the in vitro cytotoxicity of triptophenolide was evaluated by MTT assays in LNCaP and PC-3 cells. As a result, triptophenolide inhibits the growth of the LNCaP cells rather than the PC-3 cells in a significant dose-dependent manner at the concentration range of 0-5.0 µM (Fig1F). Such difference in cell growth inhibition between the LNCaP cells and the PC-3 cells of triptophenolide might be caused by its antiandrogenic activity.
To investigate whether triptophenolide exhibits its antiandrogenic activity through competitive binding with androgen in the HBP, the AR fluorescence polarization (FP) assay was performed with PolarScreen AR competitor assay kit (P3018, Invitrogen). When the tracer is free in solution, its rotational mobility is greater than when bound to the receptor, resulting in a low fluorescence polarization value. We have controlled the assay for minimal competition (DMSO vehicle), which has a maximum value of fluorescence polarization and for no receptor (tracer only), which represents the minimum value of the fluorescence polarization that can possibly be reached by a competitor. The ENZ was included as a positive control (Fig 2) . Triptophenolide reduced the fluorescence polarization value in a dose-dependent manner at the concentra- Fig2B) , which indicated that triptophenolide most probably exhibits its anti-androgenic activity via competitive binding with androgen in the HBP.
Next, we predicted the binding mode of triptophenolide in AR HBP through molecular docking using Molecular Operating Environment (MOE) version 2009.10. To date, crystal structure of AR-LBD at the antagonistic form has not been obtained. Thus we built a structural model of the WT AR-LBD with H12 at the antagonistic form, using crystal structures of the AR-LBD/DHT and ER/antagonist complexes (PDB entries: 1t65 and 3ert) as templates. Three other antiandrogens (ENZ, BIC, FLU) were also docked as reference compounds ( Figure S5) , and triptophenolide had the second most favorable docked score after ENZ (Table S4 ). The predicted binding model of triptophenolide in the antagonistic model of WT AR-LBD was shown as Fig2C. D. Triptophenolide fits the HBP of AR quite well (Fig2C), and it is assumed to form hydrogen bond interactions with Gln711, Arg752, and Met780 as well as the hydrophobic interactions with Leu701, Leu704, Leu707, Met742, Met745, Met749, Ph4764, Met780, Leu873 and Phe876 at the HBP (Fig2D), which indicates that triptophenolide should bind at the HBP in a high specificity.
To determine whether triptophenolide would modulate AR protein expression, we further examined the AR protein levels during triptophenolide treatment. Western blot analysis indicated triptophenolide effectively suppressed AR protein expression in LNCaP cells in a dose-dependent manner at 50 nM, 500 nM and 5 µM for 24 hours (Fig 3A) . Thus, besides competitive binding with androgen in HBP, triptophenolide is also able to exert the antiandrogen potency through the downregulation of the AR protein level. Upon activated by androgen, the AR translocates into the nucleus where it binds ARE sites of DNA. Therefore, the confocal assay was done to evaluate the AR nuclear translocation in presence of triptophenolide. As a result, in presence of 1nM DHT, the ratio of nuclear versus cytoplasmic AR in triptophenolide (5 µM) treated cells was comparable to ENZ (500 nM) treated cell, threefold reduced relative to DHT alone (Fig 3B) . It indicates that triptophenolide is able to inhibit DHT induced AR nuclear translocation and further confirms that triptophenolide is a bona fide antiandrogen.
Here, we firstly discovered that the TCM herb Tripterygium wilfordii could efficiently inhibit the AR transcription activity. Further we identified triptophenolide from Tripterygium wilfordii as a pan-antagonist for wild-type and mutant ARs. Specially, triptophenolide has high binding affinity with AR, and inhibits the activity of F876L mutant AR which turns ENZ from AR antagonist to agonist. In addition, triptophenolide could reduce the AR protein levels. Another resistance mechanism of ENZ during the treatment of PCa is the activation of the glucocorticoid receptor (GR) signaling 8 . It has been reported that triptophenolide is also an inhibitor of GR 21 , which could overcome the resistance caused by the bypassing pathway activation of GR. Thus, triptophenolide may offer an interesting anti-PCa lead compound for the further optimization. Moreover, the work further supports that the TCM is able to provide a potential resource of therapeutic agents for PCa, and 3 our strategy used here could also be extended to other TCM herbs to search for novel antiandrogens or other anti-PCa compounds.
Fig. 1.
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